Form 4: Gossamer Bio Reprices CEO's Stock Options to $0.45

Gossamer Bio, Inc. has repriced President and CEO Faheem Hasnain's outstanding stock options to an exercise price of $0.45 per share, effective March 19, 2026.

Summary

• Gossamer Bio, Inc. (GOSS) executed a one-time repricing of certain outstanding stock options for President and CEO Faheem Hasnain.
• The exercise price for these options was reduced to $0.45 per share, effective March 19, 2026.
• A total of 6,825,000 stock options were repriced.
• The original exercise prices of these options ranged from $0.838 to $22.1 per share.
• All other terms and conditions of the repriced options, including vesting schedules and terms, remain unchanged.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed signal. While it re-incentivizes the CEO, it also highlights past stock underperformance and can be perceived negatively by shareholders due to potential dilution and governance concerns.

Positives

• The repricing significantly lowers the exercise price for 6,825,000 stock options held by President and CEO Faheem Hasnain, making them more 'in-the-money' and increasing their intrinsic value.
• This move could re-incentivize the CEO by restoring value to previously underwater options, aligning his interests with future stock price appreciation from the new, lower base.

Negatives

• Stock option repricings can be viewed negatively by existing shareholders as they often occur when the stock price has fallen significantly, effectively rewarding executives for past underperformance.
• The repricing could signal a lack of confidence in the company's ability to reach the original, higher exercise prices in the near term.
• It may lead to shareholder dilution if the repriced options are exercised at a much lower price than the market value at the time of exercise.

Risks

• Repricing options can create a perception of management being rewarded despite poor stock performance, potentially impacting investor confidence.
• The lower exercise price might reduce the incentive for management to achieve significantly higher stock prices compared to the original, higher strike prices.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the effective date of the option repricing and the remaining terms of the options.

Management Comments

• The filing indicates that the Issuer approved a one-time repricing of certain outstanding stock options, reducing the per share exercise price to $0.45, while all other terms and conditions remain in full force and effect.

Industry Context

StockSavvy.ai notes that option repricings are a common practice in the biotechnology and pharmaceutical sectors, particularly for companies whose stock prices have experienced significant declines. This strategy aims to re-motivate key executives by restoring the incentive value of their equity awards, which may have become 'underwater' due to market conditions or clinical trial outcomes. While it can help retain talent, it often raises questions about corporate governance and alignment with shareholder interests, especially when competitors might opt for new grants at current market prices rather than repricing existing ones.

Comparison to Industry Standards

• Repricing underwater stock options is a practice seen across various industries, particularly in volatile sectors like biotech. For instance, companies like AcelRx Pharmaceuticals and MannKind Corporation have historically undertaken similar repricings to retain and incentivize management after periods of stock price decline.
• The reduction of exercise prices to $0.45 from significantly higher values (up to $22.10) is a substantial adjustment, reflecting a significant drop in the company's stock price since the original grant dates. This magnitude of repricing is not uncommon when a company's valuation has been severely impacted, aiming to bring the options back into a range where they can serve as a meaningful incentive.
• Compared to granting new options at current market prices, repricing existing options can sometimes be viewed as less dilutive in terms of the total number of shares, but it effectively transfers value from existing shareholders to option holders by making previously worthless options valuable again.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and rewarding management for past underperformance; however, it could also re-incentivize the CEO for future growth.
• Employees (other option holders): May create an expectation for similar repricings or impact morale if only senior executives benefit.
• Management (Faheem Hasnain): Significantly positive impact as previously underwater options regain value, increasing personal wealth potential and motivation.

Next Steps

• The filing does not explicitly mention future actions or milestones beyond the effective date of the repricing and the continued vesting of the options.

Key Dates

Recommendation

While the repricing benefits the CEO and could re-incentivize management, it often signals past underperformance and can be viewed negatively by shareholders. The immediate impact on the stock price might be neutral to slightly negative due to governance concerns, but the long-term effect depends on whether the re-incentivized management can deliver future growth. Therefore, a 'hold' recommendation is appropriate, awaiting further operational updates and financial results to assess the effectiveness of this re-incentivization.

Keywords

Gossamer Bio, GOSS, Stock Options, Repricing, Executive Compensation, Faheem Hasnain, SEC Form 4, Insider Transaction, Equity Compensation